Targets › PTGER3
8 programs from 8 companies in 8 trials: 4 Phase 4, 2 Phase 2, 1 Phase 1, 1 Phase 3; Other, Gastroenterology, Oncology; next expected readout Dec 2026.
Receptor for prostaglandin E2 (PGE2). The activity of this receptor can couple to both the inhibition of adenylate cyclase mediated by G(i) proteins, and to an elevation of intracellular calcium. (UniProt, P43115)
Open in Phaseline: the race on PTGER3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Northwestern University | Misoprostol Prostanoid EP3 receptor agonist | PTGER3 | Phase 4 | Fibroids, Uterine | Dec 2026 |
| Chinese University of Hong Kong | Misoprostol Prostanoid EP3 receptor agonist | PTGER3 | Phase 4 | Active Peptic Ulcer Disease/GI Bleeding | Dec 2026 |
| HaEmek Medical Center, Israel | Dinoprostone Prostaglandin E2 receptor agonist | PTGER1, PTGER4, PTGER2, PTGER3 | Phase 4 | Induction of Labor | Jan 2027 |
| Kafrelsheikh University | Misoprostol Prostanoid EP3 receptor agonist | PTGER3 | Phase 4 | Misoprostol | – |
| Stony Brook University | Misoprostol Prostanoid EP3 receptor agonist | PTGER3 | Phase 3 | Postpartum Hemorrhage | Jan 2027 |
| Ghufran Dhari Awad | Prostaglandin E1 Prostaglandin E1 receptor agonist | PTGER1, PTGER2, PTGER3, PTGER4 | Phase 2 | Accelerated Orthodontic Tooth Movement | Dec 2026 |
| Indiana University | misoprostol Prostanoid EP3 receptor agonist | PTGER3 | Phase 2 | Pregnancy | Dec 2027 |
| Montefiore Medical Center | Misoprostol Prostanoid EP3 receptor agonist | PTGER3 | Phase 1 | Cervical Preparation | Jun 2027 |
Accelerated Orthodontic Tooth Movement (1) Cervical Preparation (1) Postpartum Hemorrhage (1) Induction of Labor (1) Active Peptic Ulcer Disease/GI Bleeding (1) Fibroids, Uterine (1) Misoprostol (1) Pregnancy (1)
small molecule (8)
Ghufran Dhari Awad (1) Montefiore Medical Center (1) Stony Brook University (1) HaEmek Medical Center, Israel (1) Chinese University of Hong Kong (1) Northwestern University (1) Kafrelsheikh University (1) Indiana University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.